Medication and method of complex therapy of patients with diabetes mellitus

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the pharmaceutical industry, namely to a medication for the complex therapy of patients with type 2 diabetes mellitus and a method of the complex therapy of patients with type 2 diabetes mellitus. The medication for the complex therapy of patients with type 2 diabetes mellitus contains a cleaned and dried rhizome of Curcuma longa in the form of powder with the specified size of particles. The method of the complex therapy of patients with type 2 diabetes mellitus consists of the daily intake of the cleaned and dried rhizome of Curcuma longa in the form of powder with the specified size of particles twice per day after dinner and supper at the background of the intake of pelleted hypoglycaemic agents without changing the dose and scheme of the drug therapy.

EFFECT: medication produces a direct stimulating impact on β-cells of the pancreas and ensures the development of a hypoglycaemic effect, including early stages of the disease development.

3 cl, 1 dwg, 5 tbl

 

The invention relates to medicine, veterinary medicine, herbal medicine, food and pharmaceutical industry, namely to the means for regulating blood sugar in patients with type II diabetes, and involves the use of herbal remedies with healing properties.

The invention can be used to restore carbohydrate metabolism at the stage of breaking tolerance to glucose.

Diabetes mellitus is a metabolic disease associated with dysfunction of the endocrine glands, mainly the pancreas, occurs worldwide and shows a tendency to a gradual increase. Diabetes mellitus of the second type is a violation of carbohydrate metabolism caused by insulin resistance and relative insulin deficiency or defective insulin secretion with or without insulin resistance.

Among the population of diabetics most of it suffers from sugar diabetes of the second type. After the appearance of insulin resistance, i.e. a condition in which normal dose of insulin causes a lower level of biological action than in the normal glucose tolerance is maintained or slightly attenuated, while the pancreas can maintain sufficient insulin secretion to overcome insulin resistance. After that�on how began to show the insufficiency of the function of beta cells, glucose tolerance was rapidly deteriorating and developing diabetes. Insulin resistance is an important pathogenic factor of diabetes mellitus type 2, a metabolic disorder of sugar is usually accompanied by a violation of the metabolism of fat. A key goal in the treatment of diabetes is the need to reduce insulin resistance, regulate the rate of metabolism of sugar and fat and prevent complications in the pathogenesis of diabetes mellitus of the second type.

Insulin resistance is the main trigger mechanism, against which the phenomenon of hyperinsulinism, then over time under the influence of hyperglycemia β-cells zachariasse, die and gradually the level of insulin decreases until the development of the absolute insulinotropic.

Insulin resistance is a kind of biological response of peripheral tissues to the effects of endogenous or exogenous insulin. The authors believe that insulin resistance of muscle tissue is not only the earliest, but probably genetically defined defect that significantly precedes the clinical manifestation of diabetes mellitus (DM) type 2. In the pathogenesis of this type of diabetes involves defects in insulin secretion, manifested in the loss or significant reduction �ervay phase glucoseinduced insulin secretion, in reducing or inadequate stimulation of insulin secretion, impaired pulsating insulin secretion, increased secretion of proinsulin, reverse the reduction of insulin secretion due to glucose - and lipotoxicity, and possibly other factors.

According to the modern concept of treatment of patients with diabetes, treatment is based on early diagnosis of disorders of carbohydrate metabolism (even at the stage of breaking tolerance to glucose) and on the combination of non-pharmacological (dietary recommendations, adequate physical activity and training) and pharmacological effects (using an oral glucose-lowering drugs) in the early stages of disease development.

For the treatment of diabetes and its complications as the active components of medicinal plants or their extracts, including in Ayurvedic practice. Ayurvedic medicine professes a holistic approach to the person. She considers that chronic diseases are systemic diseases that arise due to the damage of many organs. Ayurvedic practice allows not only to identify the disease in its clinical stage, but also to determine incipient disease, and predisposition to certain diseases.

Turmeric (lat. Curcuma) is a genus of monocotyledonous herbaceous plant of the Ginger family. Kornev�schA and stems of many species of this genus contain essential oils and yellow colourings (curcumin) and cultivated as a spice and medicinal plants. The greatest distribution as a spice received turmeric (Curcuma longa) (other names - Turmeric home (Curcuma domestica), tumeric), powder of dried roots, which is known as the spice turmeric.

Many years of studying the biological activity of extracts of the plant Curcuma longa ethanolic, methanolic, aqueous, etc. (Ammon H. P. T., M. A. Wahl, 1991; R. C. Srimal, 1997) allowed us to identify the main biologically active substances contained in the rhizome of Curcuma longa and explain the mechanism of their action. In the composition of the chemical components of extracts of turmeric carbohydrates found between 4.7 and 8.2 per cent), essential oils (2,44%), fatty acids (1.7 to 3.3 per cent), curcuminoids (curcumin, demethoxycurcumin and bisdemethoxycurcumin), the content of which is approximately 2% but may reach 2.5-5.0% of dry mass, as well as other polypeptides, such as turmeric (0.1% of dry extract) (L. Srinivas, V. Shalin K., Shylaj M., 1992).

Effective the beginning of the rhizome of Curcuma longa are curcuminoids (curcumin, demethoxycurcumin and bisdemethoxycurcumin), the use of which in the treatment of diabetes is based on the ability to modulate lipid profile in animals with STZ-nicotinamide-induced diabetes (Pari l, Murugan P., 2007). Spice significantly reduced the level of blood glucose and increased insulin content in the blood plasma, as well as reduced cholesterol, triglyce�ides, free fatty acids, phospholipids and decreased the activity of 3-hydroxy-3-methylglutaryl-coenzyme a reductase (hydroxymethylglutaryl (HMG) CoA reductase). Observed curcumin-induced increase of high density lipoprotein in diabetic animals (P. Murugan, L. Pan, 2006). Inhibition by curcumin diabetic and inflammatory processes shown G. Varquez and co-authors (2007) models of obesity in mice on the background of insulin resistance. Curcumin slowed the development of diabetes in leptin-deficient mice (line 06/0b/C57B 1/6J) contained in high-fat diet, with the decline in insulin resistance and increased levels of glycosylated hemoglobin A1c. The effects of curcumin reduced the infiltration of macrophages in white adipose tissue, increased production of adiponectin, and decreased the activity of NF-κ in the liver, hepatomegaly and maintenance of inflammation markers of liver tissue (Weisberg, S. P. et al., 2008).

As curcumin and its metabolite tetrahydrocurcumin reduced the level of glucose in the blood, increase the level of insulin in blood plasma and modulated the level of key enzymes of hepatic tissue in STZ-induced diabetic rats through modulating the effects of oxidative stress and a decrease in the rate of lipid peroxidation (Murugan p, Pari L., 2006).

Famous work, which presents researchers obtained sugar-e�effect in patients with type II diabetes by reducing the amount of free fatty acids in serum (FFAs) using curcuminoids - Curcuminoids (research methods - a double blind, placebo). The use of curcuminoids is possible to reduce the content of blood glucose and improve insulin resistance with increase of fatty acid oxidation in skeletal muscle of diabetic rats.

Curcuma longa is used in the compositions of medicinal herbs and plants to reduce the level of glucose in the blood ("Hyperglycemic activity of Curcuma longa of Tank, R.; Sharma, N.; Dixit, V. P. of the Reproductive Physiology Section, Department of Zoology, University of Rajasthan, Jaipur which appeared in the Indian Zoologist, v.12(3-4): p.321-322, 198), but in some works it is noted that curcumin is more effective for blood sugar than Curcuma longa (Effect of turmeric on the enzymes of glucose metabolism in diabetic rats and published in the Journal of Herbs, Spices and Medicinal Plants. V. 10(1).

In an experimental model obtained a substance isolated from the plant Curcuma longa, influencing the biochemical structure of bile (Pat. Of the Russian Federation No. 2030182, MKI AC 35/78, publ.: 10.03.1995, according to 27.09.2012 - terminated). In an experimental model found that Curcuma longa has an impact on the secretion and bile production, increases the amount and rate of secretion of bile, changes the chemical composition of bile: increases the amount of bile acids, increases holatoholesterinovyj coefficient, increases the secretion of bilirubin. This increases the colloidal stability of bile, and create conditions to prevent the formation of gallstones.

Known complex curcuminoids, CH� - decreasing activity of cyclooxygenase-2 in the experiment (Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2,. United States Patent 7,682,636 Babish, et al. March 23, 2010). The inventive composition provides synergistic anti-inflammatory effects in response to physical or chemical damage in animals or impaired immune response under the influence of the biological agent of unknown etiology.

The method of treatment of diabetes in experimental animals, comprising administering the composition curcuminoid and a component selected from the group consisting of tetrahydroisoquinoline or di-isohumulone.

Other aspects of the invention proposed composition of two or more ingredients from the group of antioxidants, vitamins and minerals; from monosaccharides, amino acids, glucosamine, protein, fat, acetates or glutathione.

On the stage of the present study the effect of Curcuma longa and its components on carbohydrate metabolism in patients with type II diabetes has not been studied. There is only a single work, the results of the experiment show that turmeric retard the development of streptozotocin-induced diabetes mellitus in albino rats in the experiment and thus contributes to the normalization of lipid metabolism (Babu P. S., SrinivasanK., 1995, 1997).

Renowned pharmaceutical composition for the regulation of sugar and fat in the blood, its preparation and use (Pat. Of the Russian Federation No. 2409381, priority 31.07.2007, publ. PCT application:WO 2009/015515 20090205, 2009). Pharmaceutical compositi� contains a collection of Chinese medicinal plants or their extracts in various mass parts, including a mass fraction of the rhizome of turmeric (Rhizoma Curcuma longa).

Known herbal mixture according to the Korea patent (Patent Application No.KR20020011015, MKI AC/37; UK/73; AC/815; ART/10; 2002-02-07; FORMULATION FOR TREATMENT OF DIABETES,KIM TAE BUNG [KR]; SHIN SEUNG CHEOL [CN]; Applicant: KOSTARWORLD [KR], KR priority 20000044392 20000731).

Proposed medicinal blend of herbs for the treatment of patients with insulin-independent diabetes and its complications, demonstrating therapeutic and prophylactic effects in the form of lowering the blood sugar. The mixture includes a set of medicinal plants, which in powder form is present Curcuma longa Rhizoma (root), component 5 weight units in the total amount of ingredients- 30:10:10:10:5:5:5:7:5:5:3. All the ingredients are dried and mixed in a blender to obtain a homogeneous mass.

Known composition of herbs for the prevention and treatment of diabetes and related complications (Herbal formulation for prevention and treatment of diabetes and associated complications. United States Patent 8,163,312, Int. Cl. A61K914FI, Krishnan, April 24, 2012).

According to the invention, the composition of medicinal herbs, which includes in its composition a certain percentage of curcumin from Curcuma longa rhizome (Rhizoma Curcuma longa), has anti-inflammatory and antioxidant activity, it is proposed to use in complex therapy of patients with diabetes mellitus to regulate blood sugar levels and oslabljeni� of insulin resistance.

The composition may be prepared in different pharmaceutical forms such as tablets, granules, powder, syrup, capsules, in the form of a drink, etc.

The synergistic effect obtained by the integrated effect of the herbal mixture in conducting therapeutic interventions.

This technical solution adopted by the authors for the prototype on the task at hand and the options for its solution.

However, as in all the above decisions and in the decision in United States Patent 8,163,312 Rhizoma Curcuma longa in different pharmaceutical forms is used in combination with other herbal ingredients, and to isolate the effects of Curcuma longa the composition of herbs and plants that contains more than 70 ingredients, is not possible. It is therefore impossible to assess therapeutic advantages of Rhizoma Curcuma longa separately from the rest of the ingredients.

The vast majority of examples that represent different combinations of ingredients in different weight ratios converted into a powder blend of herbs were boiled and the resulting liquid was administered to patients as a drink during the day instead of the usual drinking water. When boiling of the useful ingredients of the mixture loses its activity, which, in turn, reduces the overall bioactivity of the recommended drink.

In the patent specification there is no information and n� the examples on biosboot curcumin, its hepatoprotective activity, again due to the fact that the impact of any of the ingredients, including Rhizoma Curcuma longa do not isolate from the total mixture of herbal remedies.

The aim of the present invention is to provide means, in addition to having a hypoglycemic action hepatoprotective activity, and the use of funds in the prevention and treatment of diabetes and its complications. This object is achieved in that the means selected from the group of herbal preparations that have a direct stimulatory effect on β-cells of the pancreas and enable the development of hypoglycemic effect, including in the early stages of disease development.

The tool is a powder obtained from the rhizome (Rhizoma) Curcuma longa, comprising as a main component, curcumin, has antioxidant and anti-inflammatory properties; curcumin does not induce the formation of erosions and swoopstake on the mucosa of the gastrointestinal tract, does not cause inflammatory processes in the stomach area. Anti-inflammatory effect of curcumin in its strength is not inferior, and sometimes even exceeds the number of known anti-inflammatory drugs.

During the pilot studies have provided evidence that the remedy using turmeric encourage�should hormone products from β-cells of the pancreas, prevent hyperglycemia. Powder of rhizome of Curcuma longa has a protective and/or stimulatory effect on the cells of the endocrine portion of the pancreas (Koroshenko G. A., Subotyalov M. A., Gerasev A. D., aizman R. I., 2011).

When carrying out medical procedures with the inclusion of a powder of Curcuma longa, which extends daily care of patients with diabetes mellitus of the second type, the conclusion: the tool enhances glucose-lowering effect of therapy with drugs such as biguanides and sulfonylureas, providing a potentiating effect.

Rhizome Curcuma longa, namely its lateral roots, which, after proper drying is not in the sun and in the shade - and, after processing, retain all the beneficial constituents: essential oil, curcumin, borneol, Sabine, zingiberone, minerals and vitamins, phosphorus, calcium, iodine, vitamins B3, B2, K Especially has a high content of iron, magnesium and potassium, vitamins C, B6 and E.

From the roots of turmeric by steam distillation method to get oil, which is also a wonderful anti-inflammatory agent.

However, to achieve this goal more feasible the use of Curcuma longa in powder form, because when taking the powder active receptors of the mouth, irritation which makes it more efficient to enable the action of neuroendo�Inna system.

The remedy prepared from cleaned and dried rhizomes of Curcuma longa, crushed to a fine state, with the ultimate particle size of 0.060-0.075 mm, and is recommended as a component that extends the daily medical procedure. A large dispersion grinding allows to increase the area of absorption of all useful components of the plant in the small intestine. Fine grinding is used to increase the surface of solid materials with the purpose of increasing the rate of biochemical and diffusion processes at the interface and the greater the degree of crushing, the higher the speed of these processes. Store turmeric in a dry place in an airtight container.

In daily medical procedure includes drinking powdered rhizomes of Curcuma longa, distributed for convenience in the packets (sachets) 2-4 g (1 tsp) each: this dose is appointed for a single dose.

In patients receiving oral hypoglycemic drugs without changing the type, dose and regimen of drug therapy powder of Curcuma longa rhizome administered twice daily in a dosage of 2-4 g (1 tsp) 15 to 20 minutes after lunch and dinner. For a more complete assimilation of curcumin powder Curcuma longa recommend drink warm water in 2-3 hours.

However application of this method is not ograniczenie�above are only embodiments of the use of Curcuma longa in the treatment of diabetes and some of its complications.

The above has allowed to assume that the rhizome of turmeric can be used as a tool for the treatment of diabetes mellitus and some of its complications.

Direct data on the effect of powder of the plant Curcuma longa glucose and glycated hemoglobin levels in the blood - the main indicators reflecting the condition of patients with diabetes mellitus type 2 in the clinical setting by authors in literature. All data relate to compositions, in which one of the numerous ingredients included Curcuma longa, and to isolate the actual effect of Curcuma longa on the achievement of goals is impossible.

To clarify the mechanism of the glucose-lowering effect of the powder of the plant Curcuma longa experiments were performed on adult white males of Wistar rats (n=40) with an experimental model of diabetes mellitus.

All animals were divided into three groups. The first group was the control group, which consisted of intact animals. Animals of the second and third groups were injected 10% solution of alloxan at a rate of 0.1 ml/100 g body weight to obtain the SD. Animals of the 1st and 2nd groups were kept on a standard aft, whereas in food animals of the 3rd group was added a powder of the plant Curcuma longa at the rate of 2% by weight of the feed.

Involved in the experiment, three groups of animals were kept in standard conditions of vivarium, without about�down in the consumption of food and water. For postinjection period in all animals every three days to determine the sugar content took blood samples with a volume of 0.2 ml by the notches of the tail, and urine samples, for which rats were planted in metabolic cages for 2 hours. The concentration of glucose in blood and urine was determined by picric method on a spectrophotometer Spekol".

At the end of the experiment (on day 6 after administration of turmeric) in animals under ether anesthesia from the inferior Vena cava took blood samples of 5 ml to determine the concentration of hormones.

74,8±5,6
Table 1
The content of glucose in the blood of rats (mg %) (M±m)
Groups of animalsBackground sample1 day3 days6 days
control79,85±6,265,5±1,371,4±3,480,0±1,2
alloxan + standard feed90,7±2,2330,2±3,2*380,4±2,4*290,7±5,7*
alloxan + turmeric219,3±1,0*Δ124±3,095,6±2,8
Note: * - significant differences from control; Δ - valid differences in experimental groups

As can be seen (PL.1), intake of turmeric in the first day caused a significantly lower increase in the concentration of glucose in the blood plasma of rats after administration of alloxan compared with animals on a standard feed. At 3 and 6 days, the concentration of glucose in plasma was normal in the 3rd group of animals, while rats of the 2nd group maintained a high level of glucose in the blood.

Table 2
The sugar content in the urine of rats (mg %) (M±m)
Groups of animalsBackground sample1 day3 days6 days
control0,64±0,010,60±0,20,80±0,0750,76±0,13
alloxan + standard feed0,60±0,0311,61±2,54* 11,75±1,60*remaining 9.08±1,50*
alloxan + turmeric0,68±0,03a 9.64±1,96*4,71±0,88*1,83±0,15*Δ
Note: * - significant differences from control

Determination of glucose in urine showed that turmeric also caused a significantly smaller increase in glycosuria in rats with diabetes compared to animals undergoing conventional stern (PL.2).

Thus, the experiments confirmed previous observations that turmeric causes a decrease of glycemia and glycosuria in rats with experimental model of diabetes mellitus.

Concentrations of insulin and C-peptide in the blood - the main hormones that prevent hyperglycemia, after the administration of alloxan significantly reduced in comparison to that in intact animals, while turmeric has caused an increase of both hormones in the blood, although the concentration did not reach the control level (table.3). This allowed to conclude that turmeric stimulates the production of these hormones by β-cells of the pancreas.

Table 3
The concentration of insulin and C-peptide in plasma �Rove rats (M±m)
Groups of animalsInsulin, IU/mlC-peptide, ng/ml
control2,9±0,32,24±0,22
alloxan + standard feed1,7±0,2*1,38±0,34*
alloxan + turmeric2,3±0,32,21±0,20
Note: * - significant differences from control

Structural organization from the pancreas of rats in conditions of alloxan diabetes and use in the diet of turmeric (electron microscopic and optical research).

In conditions of alloxan diabetes was a death of a part of from, at the site of necrosis of the cells formed clusters of collagen fibers. In some cells lacked granules secret, others have observed a small number of secretory granules.

In animals on the background of alloxan diabetes were given a diet of turmeric, observed the recovery of most of the structural components of cells, characterizing their secretory and protein-synthetic function (tab.4).

Table 4
Structural organization from the pancreas of rats (M±m)
Investigated parametersControlAleksey diabetesAleksey diabetes+turmeric
Mitochondria (Vv)8,3±2,182,3±0,58*6,5±2,62
Granular endoplasmic reticulum (Vv)5,9±0,622,6±0,68*6,7±3,31
Ribosomes attached (Nv)27,7±3,1312,0±1,92*27,1±6,96
Ribosomes available polyanaline (Nv)42,8±4,3427,8±7,30*37,5±14,47
Total ribosomes (Nv)70,5±5,2439,8±made 7.16 interest*64,6±13,81
Granules of insulin (Vv)12,2±1,264,4±2,38*6,9±,30*
Note: Vv is the volume density of structures (% of cytoplasm); Nv is the numerical density of structures (number 1 μm3the volume of cytoplasm)
* - indicated values significantly different from the corresponding numbers in rats of the control group

Analysis of the morphological structure of the pancreas of rats of the control group showed that the structure of the body is normal: cells are fairly evenly with well contribuenti nuclei (Fig.1). In all experimental groups compared to control was observed necrotic changes induced by alloxan toxicity. In the analysis of the structural organization of the pancreas in rats after administration of turmeric found hypertrophy of the islets of Langerhans and submicron. In rats, using the standard feed in alloxan model of diabetes, along with changes that were observed in the group with turmeric, also marked hypertrophy and hyperplasia of the islets of Langerhans, interlobular edema, focal necrosis of tissue, pseudocysts and connective tissue replacement of acini, elements, fatty atrophy, severe proteolysis in combination with lipolysis. Thus, the reception of a powder of turmeric against SD contributed to minimal�tion structural changes of the pancreas compared with the standard feed.

Consequently, the use on the background of alloxan diabetes turmeric had a stimulating effect on the regeneration processes of the endocrine part of the pancreas. This was accompanied by restoration of the cellular composition of islets and intracellular reparation of from, as not noted areas of collagenase interstitium in place from necrotic, as in the group of rats with alloxan diabetes; in addition, the concentration of cytoplasmic organelles was not different from values in the control.

Morphological data indicate the regenerative effect of turmeric on cells of the islets of Langerhans of the pancreas in diabetes that increases production of insulin and C-peptide and a decrease in the concentration of glucose in the blood.

The conclusion: in the experiment, the authors noted the ability of turmeric to act on β-cells of the pancreas and reduce the glucose level in blood.

Clinical studies

The study included patients with diabetes of the second type with a disease duration of at least one year, trained the basics of nutrition in diabetes and undergoing therapy oral hypoglycemic drugs for at least 3 months but have not reached the desired level of glycemic control.

Exclusion criteria from the study were: absolute� the need for insulin, the level of glycated hemoglobin (Nwas) more than 9%, ketosis, ketoacidosis, the presence of persistent chronic infection, severe comorbidities and complications of diabetes requiring transfer to insulin therapy, renal and hepatic failure, acute ischemic stroke and myocardial infarction in the previous 6 months prior to the study.

Sampling of blood was performed: at baseline, after 1.5 and 3 months from the start of administration in daily medical procedure of turmeric powder. The study did not anticipate changes in the type, dose and regimen of antidiabetic drug therapy, which in itself does not lead to the target blood glucose levels.

The study evaluated the level of glycated hemoglobin (Nwas), preprandial (fasting) and postprandial (after eating) blood glucose.

The level of glycemia was determined by the glucose oxydase method in plasma, NVS - standard method for the apparatus D10.

In total the study involved 19 patients with diabetes mellitus of the second type (17 women and two men) with disease duration of 6.0±6,25 years (from 1 year to 28 years). The average age was 61.5 years±6,28 years (with a range from 49 to 73 years). All patients complied with the recommendations on nutrition and physical activity and was taking oral hypoglycemic drugs.

Two weeks from �began receiving powder turmeric one patient in connection with the appearance of heartburn refused further participation and were withdrawn from the study. The remaining 18 participants of adverse reactions during the entire period of observation was not. In contrast, five of the 19 people on the use of turmeric noted improvement in General condition and increase of tolerance to physical loads. One patient had decreased pain in the joints of the hands and feet. One patient noted the disappearance of bulimia and normalization of appetite.

Dynamics of the level of glycemic control are reflected in table 5. A statistically significant reduction in the whole group noted after 3 months.

It should be noted that while taking turmeric in 5 patients on concomitant therapy with biguanides and sulfonylureas (PSM), he had a bit of hypoglycemia (27,8%), which was the basis of lower doses (PSM) in 3 patients and cancellations in one patient.

R 2-3
Table 5
The content of blood glucose, glycated hemoglobin, body weight and waist circumference in patients with type II diabetes in the dynamics of the reception of turmeric powder (M±m)
IndicatorsVisit 1 (before treatment) (n=18)Visit 2 (after 1.5 months). (n=18)Visit 3 (after 3 months). (n=18)P 1-2P 1-3
MON, mmol/l7,38±0,25of 6.79±0,456,36±0,31*≥0,1≥0,1≤0,01
BCPs, mmol/l9,76±0,51to 8.38±0,767,03±0,31*≥0,1≥0,1≤0,01
Nuas, %7,54±0,187,40±0,367,02±0,15*≥0,1≥0,1≤0,05
Body weight, kg90,5±4.490,1±4,288,6±4,2≥0,1≥0,1≥0,1
FROM, cm108,6±3,4109,0±3,2of 107.2±3.2≥0,1≥0,1≥0,1
Note: MON - preprandially glycemia; BCPs NAS - glycated hemoglobin; FROM - waist circumference; * - significant differences from 1 visit (before treatment)

The effect of the combined impact of the powder (Rhizoma) as Curcuma longa on the pancreas, and tissues sensitive to insulin, namely glycated hemoglobin as an indicator of capture tissue glucose under the influence of insulin, long-lasting changes in the content of glucose in the blood. The result is a lower dose of antihyperglycemic drugs used.

The results show that the inclusion of a powder of Curcuma longa as a component that extends the daily treatment of patients with type II diabetes, enhances glucose-lowering effect of therapy with biguanides and sulfonylureas, providing a potentiating effect.

Thus, thanks to the author chosen option therapeutic effects through a combination of herbal remedies and pharmacological glucose-lowering drugs, including at early stages of disease development, achieved better consistency and increased efficiency of treatment of patients.

1. Remedy for the treatment of patients with diabetes mellitus type 2, characterized in that it contains cleaned and dried rhizome of Curcuma Longa in the form of powder with particle size is 0.060-0,075 mm.

2. �] the complex therapy of patients with diabetes mellitus type 2, characterized in that, every day cleaned and dried rhizome of Curcuma Longa in the form of powder with particle size is 0.060-0.075 mm twice a day for 15-20 minutes after lunch and dinner while taking oral hypoglycemic drugs without changing the dose and schedule of medication therapy.

3. A method according to claim 2, characterized in that the powder of the rhizome Curcuma longa washed down with warm water 2-3 times.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to therapy and endocrinology, and can be used in treating patients suffering type 2 diabetes mellitus. That is ensured by a continuous exenatide delivery by implanting into a patient into an osmotic delivery device comprising an impermeable container, a semi-permeable membrane, an osmotic mechanism integrated into the container and adjoining the semi-permeable membrane, a piston adjoining the above osmotic mechanism; the above piston forms a movable seal with an inner surface of the container and divides the container into a first chamber comprising the osmotic mechanism, and a second chamber comprising a suspension formulation, and a diffusion adjustor. The suspension formulation contains a particle formulation containing exenatide particles having a diameter of less than 10 to 30 mcm. The delivery formulation contains a solvent specified in a group consisting of benzyl benzoate, lauryl lactate and lauryl alcohol, and polyvinylpyrrolidone polymer. The delivery formulation has a viscosity of approximately 10,000 poise to approximately 20,000 poise at 37°C. The continuous exenatide delivery in the therapeutic concentration is ensured for 5 days or less. The continuous exenatide delivery from the osmotic delivery device in a dose of exenaide of 10 mcg/day, 20 mcg/day, 30 mcg/day, 40 mcg/day, 60 mcg/day, and 80 mcg/day can be effected through at least three months.

EFFECT: method enables the effective treatment of the given pathology by the fast achievement and long maintenance of the exenatide concentration to be completed rapidly with no constant injections or oral administration.

15 cl, 20 tbl, 21 dwg, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a citrate of a compound described by formula (II) below, and a pharmaceutical composition containing said citrate.

EFFECT: experimental results of the present inventions prove that said citrate can inhibit activity of phosphodiesterase type 5 and can be used for treating erectile dysfunction, for inhibiting thrombocyte aggregation and treating thrombosis, for reducing pulmonary hypertension and treating cardiovascular diseases, asthma and diabetic gastroparesis.

2 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to a compound of formula (I) or its pharmaceutically acceptable salts of formula (I), wherein X represents O, S; Y represents O, S; R1 independently represents H, alkyl; G1 represents ethyl; each G2 and G3 are independently specified in H, alkyl, trifluoromethyl, halogen, nitro, amido, cyano and tetrazolyl. The invention also refers to a pharmaceutical composition possessing activating action on peroxisome proliferator activated receptors subtype α, subtype δ and subtype γ and containing an effective amount of the compound of formula (I) or its pharmaceutically acceptable salts. The compounds of formula (I) are applicable for treating or producing a drug preparation for treating or preventing the diseases associated with peroxisome proliferator activated receptors subtype α, subtype δ and subtype γ. The compounds of formula (I) are produced by a reaction of the compound of formula (III) and the compound of formula (IV) when heated in acetonitrile under reflux in the presence of potassium carbonate to produce the compound of formula (II), to saponify the compound of formula (II) in alcoholic solution in the presence of alkali and to acidify the reaction mixture to produce the compound of formula (I). X, Y, R1, G1, G2 and G3 have the above values; R3 represents a leaving group specified in OH, Cl, Br, I, OTs, OMs.

EFFECT: compounds of phenylpropionic acid possessing the activating action on peroxisome proliferator activated receptors (PPARα, δ, γ).

15 cl, 2 ex

FIELD: medicine.

SUBSTANCE: agent for treating diabetes mellitus involving dry aqueous extract of Geranium Dieisianium Knuth and dry aqueous extract of Uncaria tomentosa (Willd) D.C. bark enclosed into gelatine capsules. A method of treating diabetes mellitus provides prescribing the above agent in a daily dose of 180-360 mg after a meal. The above agent enables treating diabetes mellitus effectively by reducing dosages of blood glucose lowering drugs.

EFFECT: agent causes the positive effect on carbohydrate metabolism and possesses non-specific immunomodulatory action.

2 cl, 5 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: object of the invention is a method and a pharmaceutical composition in the form of a water-alcohol solution of ethanol 30-60° and water 40-70%, wherein at least one hypoglycaemic active substance is stably and completely dissolved, to be used by administering through the oral mucosa as a therapeutic agent in accurate treatment of postprandial hyperglycemia accompanying type II diabetes mellitus in a human or animal; wherein the water-alcohol solution in the composition has a volume of less than 2 ml, wherein an amount of 250mg or less of the above active substance is stably and completely dissolved, while the hypoglycaemic active substance is specified in lipophilic or amphiphilic active substances, such as gliclazide, glinides, incretins and glyphins. The invention also refers to a method for preparing this dosage form.

EFFECT: preparing the therapeutic agent for treating postprandial hyperglycemia accompanying type II diabetes mellitus.

9 cl, 20 ex

FIELD: chemistry.

SUBSTANCE: invention refers to gene engineering, more specifically to producing the peptide GLP-1, modified by an oligosaccharide chain, and can be used in medicine for treating or preventing diseases associated with GLP-1. In the peptide GLP-1 with SEQ ID NO: 2 or SEQ ID NO: 3 two amino acid peptides are substituted by an amino acid modified by a complex bi-antennal oligosaccharide chain, and wherein each of the centres is specified in a group consisting of positions 18, 22, 26, 30, 34 and 36 in the peptide GLP-1 with SEQ ID NO: 2 or SEQ ID NO: 3. The above modified peptide GLP-1 can involve the deletion, substitution or attachment of 1-5 amino acids, except for the amino acids modified by the oligosaccharide chain.

EFFECT: invention enables producing the peptide GLP-1 modified by the oligosaccharide chain, which shows the stronger activity of blood glucose suppression and twice increased half lifetime as compared to GLP-1 with SEQ ID NO: 3.

24 cl, 5 dwg, 6 tbl, 16 ex

Oxyintomoduline // 2542362

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to peptide analogues of oxyintomoduline (OXM, glucagon-37), which can be modified for providing the stability of cleavage and inactivation with dipeptidyl peptidase IV (DPP-IV) for increasing a half-life time in vivo of the peptide analogue alongside with enabling the peptide analogue acting as a double agonist GLP-1/glucagon receptor (GCGR).

EFFECT: peptide analogues are applicable for treating metabolic disorders, such as diabetes and obesity.

16 cl, 16 dwg, 11 tbl, 12 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula , wherein A represents CRaRb or -CH2-CH2-; R1 represents hydrogen or alkyl; R2 represents hydrogen or alkyl; R3 represents alkyl, cycloalkyl, cycloalkylalkyl, aryl, substituted aryl, 1H-pyrazolyl or substituted 1H-pyrazolyl, wherein substituted aryl represents aryl substituted by 1-3 substitutes independently specified in alkyl, halogen and halogenalkyl, and wherein substituted 1H-pyrazolyl represents 1H-pyrazolyl substituted by 1-3 substitutes independently specified in alkyl and aryl; Ra represents hydrogen or methyl; Rb represents hydrogen or methyl; or Ra and Rb together with a carbon atom, to which they are attached, form cyclopropyl, cyclobutyl or cyclopentyl; provided Ra and Rb both represent hydrogen, or both represent methyl simultaneously, R3 represents (1-methylcyclopropyl)methyl, which possess the inhibitory action on 11b-HSD1.

EFFECT: preparing the compounds, which possess the inhibitory action on 11b-HSD1.

15 cl, 1 tbl, 32 ex

FIELD: medicine.

SUBSTANCE: invention refers to a method of treating a condition or a disease, wherein the insulin administration is considered to be effective; the method involves administering effective doses of an insulin derivative representing insulin NεB29-(Nα-(HOOC(CH2)14CO)-y-L-GIu) des(B30) into a patient in need thereof, wherein the above insulin derivative has a prolonged time-action profile, and the above doses are to be administered every 24 to 336 hours.

EFFECT: treating by administering the above insulin through extended intervals of time and simplifying the therapeutic regimens for patient's comfort.

11 cl, 4 ex, 5 tbl, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to pharmaceutics, namely to an aqueous pharmaceutical composition containing insulin, an insulin analogue or an insulin derivative and methionine; as well as to a method for preparing and using it for treating diabetes mellitus, and to a therapeutic agent for treating diabetes mellitus.

EFFECT: group of inventions provide stability of the above proteins in solution.

29 cl, 10 ex, 6 dwg

FIELD: chemistry.

SUBSTANCE: invention refers to using an oral composition containing steviol, which improves the human hair or animal fur/feather/scale look. Using steviol in preparing the oral composition of nutriceuticals or a nutrient composition for improving the human hair or animal fur/feather/scale look.

EFFECT: invention provides improving the human hair or animal fur/feather/scale look more effectively.

7 cl, 4 dwg, 5 tbl, 13 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises administering a homeopathic agent. The agent "Liarsin" is used, which is administered subcutaneously before calving into the biologically active points in the centre of the front and rear udder parts.

EFFECT: invention is highly effective for prevention of parturient paresis in cows.

4 cl, 2 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents method of obtaining microcapsules of medication, which possess supermolecular properties, by method of precipitation with non-solvent, characterized by the fact that as medication applied is powder of unabi berries, preliminarily dissolved in butanol, as envelope - carrageenan, which is precipitated from solution in acetone by addition as non-solvent of ethanol and water, with the following drying at room temperature.

EFFECT: invention ensures simplification and acceleration of process of obtaining microcapsules, reduction of loss in the process of obtaining microcapsules (increase of output by weight).

2 ex, 18 dwg

FIELD: medicine.

SUBSTANCE: method includes the preparation of a carious cavity, opening the tooth cavity, creation of an access to root canals, extension of their orifice. Removal of a decayed material from the root canals and their drug treatment are carried out. After that, performed are: wide opening of the apical tooth orifice, mechanical and drug removal of periapical pathological exudative formations in the focus of periapical inflammation through the root canal. Before filling the canal with a filling material the gel "Lamifaren" is introduced into the focus of periapical destruction. Such introduction is performed three times after a day under temporary stopping. The gel "Lamifaren" is introduced inside in a dose of 50 g 2 times per day for 30 days.

EFFECT: application of the invention accelerates bone tissue regeneration due to the active release of an active substance calcium alginate, provides stable remission due to local and systemic detoxifying effect.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to methods of purification and health improvement of an organism. For this purpose therapeutic starvation for not fewer than 5 days in case of a 7-day programme and for not fewer than 7 days in case of a 9-day programme is carried out. The duration of a recovery period constitutes two days. Food intake is realised nine times per day each day both in the process of therapeutic starvation and in the recovery period. In the period of therapeutic starvation the first food intake includes bee products "APIGRANULES 2" in a dose of one teaspoon, "KHINAZI balm" in a dose of one teaspoon, "A-P-V" in a dose of one teaspoon, "APITOK" in a dose of one teaspoon, "Antihelm phyto" - one capsule and still mineral water - one glass. The second food intake includes a drink with ginger, lemon juice, garlic and mint, honey - one teaspoon and one glass of apple-carrot juice. The third food intake supposes an intake of bee products "APIGRANULES 2" in a dose of one teaspoon, "KHINAZI balm" in a dose of one teaspoon, "A-P-V" in a dose of one teaspoon, "Antihelm phyto" - one capsule and still mineral water - one glass. The fourth food intake includes a drink with ginger, lemon juice, garlic and mint, honey - one teaspoon and one glass of apple-carrot juice. The fifth food intake consists of tea black or green with ginger, one teaspoon of honey and one glass of apple-carrot juice. The sixth food intake consists of bee products "APIGRANULES 2" in a dose of one teaspoon, "A-P-V" in a dose of one teaspoon, "Antihelm phyto" - one capsule and one glass of still mineral water. The seventh food intake includes tea black or green with ginger, one teaspoon of honey and one glass of apple-carrot juice. The eighth food intake supposes an intake of tea black or green with ginger, one teaspoon of honey and one glass of apple-carrot juice. The ninth intake of food includes depressant tea, including mint grass, valerian root, fennel seeds, cumin seeds, epilobium or strawberry leaves and one glass of apple-carrot juice. In the recovery period in 1-st, 2-nd, 3-rd, 4-th and 6-th intakes of food the composition of products remains the same as in the process of starvation. For the fifth intake of food the patients take tea black or green with ginger, one teaspoon of honey and vegetable soup. For the seventh intake of food the patients take tea black or green with ginger, "MILK COCKTAIL WITH CHITOSAN". The eighth intake of food includes tea black or green with ginger, one teaspoon of honey, "APICAMPA" cereal. The ninth intake of food for the recovery period includes a baked apple, depressant tea. In addition, a number of procedures are carried out after each food intake during the period of therapeutic starvation and the recovery period. After the first food intake gymnastics "5 Tibetan pearls" is realised. After the second food intake exercises on training apparatuses, procedures of press-therapy, electrolypolysis and myostimulation are realised. After the third food intake exercises of therapeutic physical training or aerobics are performed. After the fourth food intake a rest in form of a walk, a halotherapy session, combined with a session of relaxation therapy are realised. After the fifth food intake a course of strip-plastic is carried out. After the sixth food intake massage by manual application with a peloid-based mixture or manual massage with honey is carried out. After the seventh food intake an infra-red sauna, shower, phytobath with medicinal herbs, honey, ginger, lemon juice is taken. After the eighth food intake a shower is taken.

EFFECT: method ensures effective health improvement of the organism with the preservation of the full value life style and a sense of a comfortable state in the starvation period, reduction of recovery period term after starvation, purification of the organism without loading on the gastrointestinal tract, weight loss, and improvement of the general state and workability of the patients.

3 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology, and can be used for the treatment of local skin I-II degree radioreactions on irradiation fields after neutron therapy in patients with head and neck malignancies. For this purpose the applications of ozonised sunflower oil with peroxide number 18% and acid number 71 mg KON/g are performed on the area of the affected skin. The impact is performed after a session of neutron therapy 1-2 times per day for 4-5 days.

EFFECT: method ensures the reduction of the number of radioreactions and skin injuries due to optimally selected parameters of the applied medication, capable of the fast arrest of pain syndrome, reduction of oedema of surrounding tissues, wound-healing action in specific irradiation conditions.

4 dwg, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to versions of cationic polyelectrolytic composition for application in personal care products and household chemicals and method of its obtaining. Composition includes: 1) cationic synthetic water-soluble polyelectrolyte, which contains (meth)acrylamide polymer and one or several of the following substances: I) cationic (meth)acrylamide monomer, and II) cationic monomer of (meth)acrylic acid, and III) hydrolysis-resistant cationic monomers, where polyelectrolyte has weight average molecular weight from approximately 10000 to approximately 2000000, charge density from, 0.001 to 2.5 meq./g, and level of acrylamide monomer that did not react constitutes less than 50 ppm, 2) surface-active substance and 3) solvent.

EFFECT: preparations, obtained on the base of composition, possess higher transparency.

17 cl, 3 dwg, 12 tbl, 106 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method of producing shea oil microcapsules. Said method is characterised by that shea oil is dissolved in dimethyl sulphoxide, the obtained mixture is dispersed in a suspension of sodium alginate in butanol in the presence of E472c, followed by addition of isopropanol and water, filtering and drying the obtained suspension of microcapsules, wherein the nucleus/polymer ratio in the microcapsules is 1:1 or 1:3.

EFFECT: invention provides a simple and fast process of producing shea oil microcapsules and increases mass output.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to using medicinal plant Gelsemium elegans Benth. and Datura metel L. blossom in preparing a therapeutic agent for eliminating or relieving acute and persistent withdrawal symptoms caused by taking a dependence-producing substance. The invention refers to pharmaceutical compositions (versions) for eliminating or relieving acute or persistent withdrawal symptoms caused by taking the dependence-producing substance, and containing Gelsemium elegans Benth. and Datura metel L. blossom in certain relations.

EFFECT: pharmaceutical compositions containing Gelsemium elegans Benth and Datura metel L. blossom are effective for the individuals suffering drug dependence.

15 cl, 12 ex

FIELD: chemistry.

SUBSTANCE: invention relates to method of simultaneous obtaining of two flavonoids - patuletine and its 7-O-β-D-glucopyranoside - patuletrine. Method consists in the following: milled edge petals of flower of high flavonoid sorts of tagetes patula are extracted with hexane, dried and r-extracted with chloroform, chloroform extract is concentrated, dry residue is dissolved in mixture of petroleum ether - chloroform, precipitated sediment is filtered, washed with petroleum ether and dried, obtained dry powder is dissolved in mixture chloroform - ethanol, precipitated sediment is filtered, washed with petroleum ether and dried with obtaining patuletine. Then, extraction of raw material, which remains after chloroform processing, is carried out with ethanol, alcohol extract is filtered and concentrated, after that, water residue is subjected to liquid phase extraction with ethylacetate, then, organic layer is concentrated, dry residue is dissolved in mixture chloroform - ethylacetate, precipitated sediment is filtered, washed with cooled ethylacetate, solution of hydrochloric acid in ethanol, ethanol and ethylacetate and dried, dry powder is dissolved in mixture ethylacetate-ethanol, precipitated sediment is filtered, washed with ethylacetate and dried with obtaining patuletrine.

EFFECT: method makes it possible to obtain highly pure samples of patuletine and patuletrine, as well as increase target product output.

4 dwg, 3 tbl, 4 ex

FIELD: medicine, oncology, amino acids.

SUBSTANCE: invention relates, in particular, to the development of an antitumor preparation based on natural substances. Invention relates to an amino acid preparation comprising at least one modified essential amino acid obtained by treatment of amino acid by ultraviolet radiation (UV) at wavelength 250-350 nm for 12-80 h at temperature 15-30oC or with ozone at temperature 15-25oC. The modified amino acid has no toxicity for health cells. Also, invention relates to a method for preparing such preparation. Invention provides the development of an antitumor preparation based on modified amino acids and expanded assortment of antitumor preparations being without cytotoxicity for normal cells.

EFFECT: valuable medicinal antitumor properties of preparation.

8 cl, 4 tbl, 2 dwg, 4 ex

Up!